Quick Links

Email Alerts


Email Address	*

Mailing Lists *

Releases

SEC Filings

Presentation

Events



Enter the code shown above.
*

Unsubscribe from email alerts

Board of Directors

Decisions regarding strategic deployment of Opexa Therapeutics' assets are made by our Board of Directors and are based upon information and advice presented by Management and key consultants and advisors to the Board.

Gail J. Maderis , ,

Gail Maderis currently serves as President and CEO of BayBio, an independent, non-profit trade association serving the life sciences industry in Northern California. She was previously President and CEO of FivePrime Therapeutics, Inc., a biotechnology company focused on the discovery and development of innovative protein and antibody drugs, and prior to that, held general management positions at Genzyme Corporation, including founder and president of Genzyme Molecular Oncology, a publicly traded division of Genzyme, and corporate vice president of Genzyme Corporation. She has served as a director of NovaBay Pharmaceuticals, Inc. since October 2010. She has been a member of several private company boards, and currently serves on The Mayor's Biotech Advisory Council of San Francisco, as well as the HBS Healthcare Initiative board.

Along with comprehensive experience in corporate development, Ms. Maderis brings to the board of directors an extensive involvement in strategic management, a successful track records of working with investors and partners to finance clinical development, a deep insight into regulatory and business policy trends impacting the biopharma industry, and a demonstrated understanding of governance issues facing emerging companies.

Ms. Maderis received a B.S. degree in business from the University of California at Berkeley and an M.B.A. from Harvard Business School.

Timothy Barabe , ,

Tim Barabe retired in 2013 as EVP and CFO of Affymetrix, Inc. Previously, he was SVP and CFO of Human Genome Sciences, Inc. and CFO of Regent Medical Limited, a U.K.-based, privately owned, surgical supply company. Mr. Barabe was also with Novartis AG for more than 20 years where he served in a succession of senior executive positions in finance and general management, most recently as the CFO of Sandoz GmbH, the generic pharmaceutical subsidiary of Novartis. Mr. Barabe serves on the board of ArQule, a Boston-based, NASDAQ-listed biotech company. Mr. Barabe received his undergraduate degree from the University of Massachusetts (Amherst) and his MBA from the University of Chicago.

Hans-Peter Hartung , , MD, PhD, FRCP ,

Professor Hartung holds the Chair of Neurology at Heinrich-Heine University, Düsseldorf, and is chairman of the Department of Neurology. He was educated at the medical schools of the Universities of Düsseldorf, Glasgow,Oxford, Harvard and Johns Hopkins, and at the Institute of Neurology, Queen Square, London. Professor Hartung is a member of various international and national societies, serving on executive boards for ECTRIMS, the European Neurological Society, the International Society for Neuroimmunology, the International Federation of Multiple Sclerosis Societies and the World Health Organization Advisory Board on Multiple Sclerosis, as well as on the editorial board of various international journals. He has written extensively on neurology, neuroimmunology, peripheral nerve disease and MS.

Michael S. Richman , ,

Michael S. Richman has served as a Director since June 2006. Mr. Richman has served as president and chief executive officer of Amplimmune, Inc. since July 2008. Mr. Richman served as president and chief operating officer of Amplimmune, Inc. from May 2007 to July 2008. From April 2002 to May 2007, Mr. Richman served as executive vice president and chief operating officer of MacroGenics, Inc. Mr. Richman joined MacroGenics, Inc in 2002 with approximately 20 years experience in corporate business development within the biotechnology industry. Mr. Richman served as a director of Cougar Biotechnology from June 2006 to July 2009. Mr. Richman obtained his B.S. in Genetics/Molecular Biology at the University of California at Davis and his MSBA in International Business at San Francisco State University. He has extensive experience in business development and strategic planning for life science companies, as well as his executive leadership and management experience.

Neil K. Warma , ,

Neil K. Warma was appointed President and Chief Executive Officer of Opexa Therapeutics, Inc. in June 2008, and is a Member of the Board of Directors. He has more than 20 years of executive level experience in the life sciences industry in the U.S., Europe and Canada. Prior to joining Opexa, Mr. Warma served as President & CEO and a member of the Board of Directors of Viron Therapeutics Inc., a privately-held clinical stage biopharmaceutical company developing a novel class of protein therapeutics. While at Viron, Mr. Warma positioned the company as a leader in the treatment of serious inflammatory disorders.

Previously, Mr. Warma held several senior management positions at Novartis Pharmaceuticals at its corporate headquarters in Basel, Switzerland, in international policy and advocacy and in global marketing. In addition, Mr. Warma was co-founder and President of MedExact USA, Inc., an Internet company providing clinical information and services to physicians and pharmaceutical companies, which was ultimately sold to a large public European firm.

Mr. Warma obtained an honors degree specializing in neuroscience from the University of Toronto and an International M.B.A. from the Schulich School of Business at York University in Toronto. He currently serves on the Board of Directors of the Biotechnology Industry Organization (BIO) and BioHouston, Inc.